Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Osteoporosis
How do you manage hepatotoxicity thought to be related to Romosozumab use?
Have you seen liver toxicity associated with Romosozumab?
Related Questions
What treatment options would you consider for a young patient with limited mobility, low bone mass and multiple vertebral compression fractures who is on dialysis for advanced kidney disease?
Do you start bisphosphonates after tapering off menopausal hormone therapy to prevent the rapid decline of bone mineral density?
What are some practical tips in distinguishing between metabolic bone disease due to chronic kidney disease and osteoporosis?
How soon after a fracture would it be safe to start anti-resorptive therapy?
Is there a maximum duration for raloxifene use?
When stopping denosumab and transitioning to PO bisphosphonate, do you wait for 6 months after the last denosumab injection to start PO bisphosphonate?
Would you use a parathyroid hormone analog for treatment of osteoporosis in a patient with mildly elevated AlkPhos of unclear etiology?
Is it safe to combine Prolia with other immunosuppressants?
What is your approach to bisphosphonate use in patients with advanced chronic kidney disease and osteoporosis?
How should we interpret DXA scans in patients with Ankylosing Spondylitis who have ankylosis of the spine?
